Information Provided By: 
Fly News Breaks for October 16, 2019
AMGN
Oct 16, 2019 | 16:43 EDT
BofA/Merrill analyst Geoff Meacham reinstated coverage of Amgen with a Neutral rating and $215 price target. The analyst has a "general lack of enthusiasm over the growth profile due to erosion from legacy brands," but also sees a promising, early stage pipeline for Amgen.
News For AMGN From the Last 2 Days
There are no results for your query AMGN
